Inj., cemiplimab-rwlc, 1 mg
Products billed under this code include Libtayo.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Libtayo.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Libtayo | Regeneron Pharmaceuticals, Inc. | 61755-0008-01 | 350 | $10,788.75 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $30.825 | +$1.157 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $29.668 | −$0.094 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $29.762 | +$1.071 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $28.691 | −$0.602 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $29.293 | +$0.596 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $28.697 | −$0.224 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $28.921 | +$0.715 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $28.206 | −$0.034 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $28.24 | +$0.543 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $27.697 | +$0.121 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $27.576 | +$0.115 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $27.461 | +$0.54 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $26.921 | −$0.002 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $26.923 | −$0.222 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $27.145 | −$0.086 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $27.231 | −$0.027 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $27.258 | +$0.006 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $27.252 | −$0.371 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $27.623 | −$0.051 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $27.674 | +$0.132 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $27.542 | −$0.035 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $27.577 | +$0.187 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $27.39 | −$0.007 | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $27.397 | – | 1 MG | Inj., cemiplimab-rwlc, 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.